Staying hydrated and using a humidifier to prevent throat dryness and irritation
CU06-1004 (endothelial dysfunction blocker) ameliorates astrocyte end-feet swelling by stabilizing endothelial cell junctions in cerebral ischemia/reperfusion injury
In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
SeekPeptides has analyzed hundreds of compounded formulations, and the glycine question comes up more than almost any other
Think of them as messengers, carrying vital instructions that influence a vast array of bodily functions, including hormone regulation, immune response, tissue repair, and more